CD70 and neoplasm: These combinations have been investigated in preclinical models and have shown potential to augment antitumour responses through multiple mechanisms, including upregulating CD70 antigen expression, enhancing the cytotoxicity of CD70‐targeted immune cells, and remodelling the immunosuppressive tumour microenvironment to overcome resistance.127